iShares U.S. Pharmaceuticals ETF (IRUI)
XHAM 
Summary
IRUI Chart
Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.
iShares U.S. Pharmaceuticals ETF (IRUI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iShares U.S. Pharmaceuticals ETF ever had a stock split?
iShares U.S. Pharmaceuticals ETF Profile
| XHAM Exchange | US Country |
Overview
The described company is an investment fund that dedicates a significant portion of its assets (at least 80%) to tracking the performance of the pharmaceutical sector in the U.S. equity market. This approach involves investing in the stocks that are part of its underlying index, as well as in other investments that share economic characteristics similar to those stocks. The underlying index focuses specifically on companies within the pharmaceuticals sector, including those involved in the manufacturing of prescription or over-the-counter drugs or vaccines. It's important to note that this fund is classified as non-diversified, meaning it may focus its investments more narrowly than diversified funds, potentially leading to higher volatility or specific sector risk.
Products and Services
This investment fund offers a focused product rooted in the pharmaceutical sector, characterized by the following:
- Component Securities Investment - The fund invests primarily in the securities that form its underlying index, ensuring that its portfolio mirrors the economic characteristics of these selected pharmaceutical companies. This strategy aims to replicate the index's performance, providing investors with exposure to the pharmaceutical industry's market dynamics.
- Investments with Economic Characteristics Identical to the Index - Beyond direct component securities, the fund seeks out investments that, while not part of the underlying index, have substantially identical economic characteristics. This broadens the fund's reach within the pharmaceutical sector, potentially capturing additional value from companies with similar profiles to those listed in the index but not included outright.
- Non-diversified Fund Structure - The fund's non-diversified status means it may concentrate its investments more heavily in fewer issuers within the pharmaceutical sector. While this could lead to higher returns if those selected issuers perform well, it also increases the risk compared to more diversified investment strategies. This aspect is crucial for investors to consider when evaluating the suitability of this fund for their portfolios.
Contact Information
